FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2885444811> ?p ?o ?g. }

• W2885444811 abstract "Cerebral palsy (CP) is the most common physical developmental disability in childhood with a prevalence of 2 to 3 per 1000 live births. β2-adrenoreceptor agonist (β2AA) are widely used for the treatment of asthma. Maternal use of β2AAs may increase the risk of adverse neuro-psychiatric health outcomes in the offspring. No study, however, has evaluated the effect of prenatal exposure to β2AAs on the risk of CP.To examine the association between prenatal exposure to β2AAs and the risk of childhood cerebral palsy.This population-based cohort study included all live singleton births in Denmark from January 1, 1997 to December 31, 2003. The information on outpatient prescriptions of β2AAs was extracted from Danish National Prescription Registry. Children born to mothers who used β2AAs from 30 days before pregnancy until delivery were categorized as the exposed. To differentiate the effect of β2AAs from the underlying indications, the exposure window was further extended to 2 years before pregnancy and the exposed groups were re-defined to represent different periods of exposure to maternal use of β2AAs (use only before pregnancy, use only during pregnancy, and use both before and during pregnancy). Cases of CP were identified from the Danish Cerebral Palsy Register. Logistic regression was used to estimate incidence odds ratio (OR) of CP.Among all the 442,278 singletons, 19,616 (4.44%) were exposed to β2AAs in utero (from 30 days before pregnancy until delivery). The risk of childhood CP was 0.21% in exposed and 0.19% in unexposed group, yielding an adjusted OR (aOR) 1.12 (95% confidence interval (CI): 0.82, 1.53). When extending the exposure time window to 2 years prior to pregnancy, no overall significant association was observed regardless of the exposure period. However, an increased risk of CP (aOR = 1.41, 95%CI: 0.92, 2.18) for maternal β2AAs use during pregnancy was observed in female offspring, especially in those born at term (aOR = 1.65, 95%CI: 1.02, 2.67). This increase was mainly attributed to an increased risk in those born to mothers who used β2AAs both before and during pregnancy (aOR = 1.81, 95%CI: 0.99, 3.33).We observed an association between maternal β2AAs use during pregnancy and an increased risk of CP in female offspring, but we could not rule out confounding by the underlying indications for β2AAs." @default.
• W2885444811 created "2018-08-22" @default.
• W2885444811 creator A5007016148 @default.
• W2885444811 creator A5007901002 @default.
• W2885444811 creator A5015993155 @default.
• W2885444811 creator A5020217316 @default.
• W2885444811 creator A5029358934 @default.
• W2885444811 creator A5037487659 @default.
• W2885444811 creator A5041564633 @default.
• W2885444811 creator A5047077004 @default.
• W2885444811 creator A5052650664 @default.
• W2885444811 creator A5069302716 @default.
• W2885444811 date "2018-08-16" @default.
• W2885444811 modified "2023-09-24" @default.
• W2885444811 title "Risk of childhood cerebral palsy following prenatal exposure to ß2-adrenergic receptor agonist: A nationwide cohort study" @default.
• W2885444811 cites W150949393 @default.
• W2885444811 cites W164686695 @default.
• W2885444811 cites W1962642834 @default.
• W2885444811 cites W1969472982 @default.
• W2885444811 cites W1987169870 @default.
• W2885444811 cites W2000943144 @default.
• W2885444811 cites W2001441877 @default.
• W2885444811 cites W2011322115 @default.
• W2885444811 cites W2011828358 @default.
• W2885444811 cites W2013811099 @default.
• W2885444811 cites W2019317402 @default.
• W2885444811 cites W2033260392 @default.
• W2885444811 cites W2038987628 @default.
• W2885444811 cites W2039489904 @default.
• W2885444811 cites W2044601279 @default.
• W2885444811 cites W2049797019 @default.
• W2885444811 cites W2052185276 @default.
• W2885444811 cites W2053540264 @default.
• W2885444811 cites W2058756209 @default.
• W2885444811 cites W2065596148 @default.
• W2885444811 cites W2068033625 @default.
• W2885444811 cites W2071969198 @default.
• W2885444811 cites W2073405838 @default.
• W2885444811 cites W2073747200 @default.
• W2885444811 cites W2077783785 @default.
• W2885444811 cites W2077941158 @default.
• W2885444811 cites W2088813254 @default.
• W2885444811 cites W2094791914 @default.
• W2885444811 cites W2102420102 @default.
• W2885444811 cites W2102924526 @default.
• W2885444811 cites W2104475671 @default.
• W2885444811 cites W2105850885 @default.
• W2885444811 cites W2108439378 @default.
• W2885444811 cites W2131032212 @default.
• W2885444811 cites W2133740109 @default.
• W2885444811 cites W2134021542 @default.
• W2885444811 cites W2142749836 @default.
• W2885444811 cites W2145125476 @default.
• W2885444811 cites W2160703315 @default.
• W2885444811 cites W2162797879 @default.
• W2885444811 cites W2164928672 @default.
• W2885444811 cites W2298839623 @default.
• W2885444811 cites W2301869456 @default.
• W2885444811 cites W2352720373 @default.
• W2885444811 cites W2418874752 @default.
• W2885444811 cites W2923453593 @default.
• W2885444811 cites W4211262191 @default.
• W2885444811 cites W4239644696 @default.
• W2885444811 cites W2232879397 @default.
• W2885444811 doi "https://doi.org/10.1371/journal.pone.0202078" @default.
• W2885444811 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6095523" @default.
• W2885444811 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30114199" @default.
• W2885444811 hasPublicationYear "2018" @default.
• W2885444811 type Work @default.
• W2885444811 sameAs 2885444811 @default.
• W2885444811 citedByCount "2" @default.
• W2885444811 countsByYear W28854448112019 @default.
• W2885444811 countsByYear W28854448112020 @default.
• W2885444811 crossrefType "journal-article" @default.
• W2885444811 hasAuthorship W2885444811A5007016148 @default.
• W2885444811 hasAuthorship W2885444811A5007901002 @default.
• W2885444811 hasAuthorship W2885444811A5015993155 @default.
• W2885444811 hasAuthorship W2885444811A5020217316 @default.
• W2885444811 hasAuthorship W2885444811A5029358934 @default.
• W2885444811 hasAuthorship W2885444811A5037487659 @default.
• W2885444811 hasAuthorship W2885444811A5041564633 @default.
• W2885444811 hasAuthorship W2885444811A5047077004 @default.
• W2885444811 hasAuthorship W2885444811A5052650664 @default.
• W2885444811 hasAuthorship W2885444811A5069302716 @default.
• W2885444811 hasBestOaLocation W28854448111 @default.
• W2885444811 hasConcept C112672928 @default.
• W2885444811 hasConcept C126322002 @default.
• W2885444811 hasConcept C131872663 @default.
• W2885444811 hasConcept C156957248 @default.
• W2885444811 hasConcept C1862650 @default.
• W2885444811 hasConcept C187212893 @default.
• W2885444811 hasConcept C201903717 @default.
• W2885444811 hasConcept C2779234561 @default.
• W2885444811 hasConcept C2779421357 @default.
• W2885444811 hasConcept C2908647359 @default.
• W2885444811 hasConcept C54355233 @default.
• W2885444811 hasConcept C71924100 @default.
• W2885444811 hasConcept C72563966 @default.
• W2885444811 hasConcept C86803240 @default.
• W2885444811 hasConcept C99454951 @default.

• next